FibroBiologics Announces Patent Application Filing for Wound Healing Using a Patch with Fibroblast Cell-Based Technology

HOUSTON, Aug. 20, 2024 (GLOBE NEWSWIRE) — FibroBiologics, Inc. (Nasdaq: FBLG) (“FibroBiologics”), a clinical-stage biotechnology company with more than 160 issued and pending patents focused on developing therapies and potential cures for chronic diseases using fibroblasts and fibroblast-derived materials, announced the filing of a patent application with the U.S. Patent Office for the use of fibroblast cell-based technology in a wound healing patch.

“Our continued exploration of therapeutic applications using fibroblast cells continues to provide unique opportunities for our wound care platform,” said FibroBiologics Founder and CEO Pete O’Heeron. “If granted, this patent will allow us to move forward with the development of a room temperature, shelf-stable dressing that can be used in the post-operative and retail settings.”